EBV mRNA vaccine for relapsed or refractory lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental mRNA vaccine designed to target cancer cells infected with the Epstein-Barr virus (EBV). It is for people with certain types of lymphoma that have come back or not responded to standard treatments. The goal is to see if the vaccine can help the immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old.
- Have a type of lymphoma that is linked to EBV (confirmed by a special test) and has not responded to treatment or has come back.
- You must have at least one tumor that can be measured on a scan.
- Be generally healthy enough for the study, with adequate organ function (like blood counts, liver, and kidney function).
- Not be pregnant, and if you could become pregnant, you must use effective birth control during and for 4 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (TCR-T cells) for people with EBV-positive lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells that have been specially trained to find and attack cancer cells carrying the EBV virus.
This early-stage trial tests an experimental vaccine designed to train your immune system to fight EBV (Epstein-Barr virus), a virus that can contribute to certain lymphomas in people with HIV. You would receive this vaccine as an add-on treatment if standard chemotherapy hasn't fully controlled your lymphoma.
This trial tests a new mRNA-based treatment for people with Epstein-Barr virus (EBV) related diseases, such as certain cancers or EBV illness after a transplant. The goal is to see if the treatment can help your immune system fight the virus and the disease.
This trial tests an mRNA vaccine to treat advanced cancers linked to the Epstein-Barr virus, such as nasopharyngeal cancer, NK/T-cell lymphoma, and stomach cancer. The vaccine teaches your immune system to fight the virus and the cancer.
This trial tests a new treatment using specially designed immune cells (called hNeo-T cells) to attack Epstein-Barr virus positive T-cell lymphoma that has come back or not responded to standard therapy. The treatment is personalized based on your tumor's unique markers and your tissue type (HLA).
This early-phase study tests a lab-made immune cell treatment (cytotoxic T-lymphocytes) for certain lymphomas and related diseases that test positive for the Epstein-Barr virus (EBV). It may help your immune system attack EBV-infected cancer cells, especially after the cancer has come back or when transplant isn’t suitable.
Hear when a new Epstein-Barr Virus Associated Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.